{
    "clinical_study": {
        "@rank": "53516", 
        "arm_group": {
            "arm_group_label": "Darunavir", 
            "description": "Patients having Acquired Immune Deficiency Syndrome (AIDS) will be taking darunavir as per recommended doses."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety data of darunavir in a natural clinical\n      practice."
        }, 
        "brief_title": "A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Acquired Immune Deficiency Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a non-interventional (a scientific study to make a clear and easy understanding of\n      the cause and effect relationship), prospective (in which the participants are first\n      identified and then followed forward as time passes), consecutive survey for collecting\n      safety and efficacy data of darunavir in treatment of Acquired Immune Deficiency Syndrome\n      (AIDS) in a natural clinical practice."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who are prescribed with darunavir for treatment of Acquired Immune\n             Deficiency Syndrome (AIDS)\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity to Prezista\n\n          -  Prezista coadministered with medicinal products that are highly dependent on CYP3A\n             for clearance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The study population will include patients who are diagnosed with Acquired Immune\n        Deficiency Syndrome (AIDS), and who are prescribed with darunavir for treatment of AIDS."
            }
        }, 
        "enrollment": {
            "#text": "3000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01741831", 
            "org_study_id": "CR100805", 
            "secondary_id": [
                "TMC114HIV4074", 
                "Prezista PMS", 
                "DRV-C-11-KR-001-V06"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Darunavir", 
            "description": "This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally for a period of 24 weeks. For treatment naive (never received treatment for AIDS) patients: Darunavir 800 mg will be adminstered along with ritonavir 100 mg once daily. For experienced patients: Darunavir 600 mg will be administered along with ritonavir 100 mg twice daily.", 
            "intervention_name": "No intervention", 
            "intervention_type": "Drug", 
            "other_name": "Prezista"
        }, 
        "intervention_browse": {
            "mesh_term": "Darunavir"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Acquired Immune Deficiency Syndrome", 
            "AIDS", 
            "TMC114", 
            "Darunavir", 
            "Prezista"
        ], 
        "lastchanged_date": "May 15, 2014", 
        "link": {
            "description": "To learn how to participate in this trial please click here.", 
            "url": "http://pam.sylogent.com/cr/CR100805"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Dae-Gu", 
                    "country": "Korea, Republic of"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Regulatory Post Marketing Surveillance of Prezista 400mg Tablet", 
        "overall_contact": {
            "email": "JNJ.CT@sylogent.com", 
            "last_name": "Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:"
        }, 
        "overall_official": {
            "affiliation": "Janssen Korea, Ltd., Korea", 
            "last_name": "Janssen Korea, Ltd., Korea Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Korea: Food and Drug Administration", 
                "Republic of Korea: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of patients with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 30 days from end of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01741831"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of patients with viral load", 
                "safety_issue": "No", 
                "time_frame": "Screening, Week 12, Week 24"
            }, 
            {
                "measure": "Number of patients with CD4 T-cell count", 
                "safety_issue": "No", 
                "time_frame": "Screening, Week 12, Week 24"
            }
        ], 
        "source": "Janssen Korea, Ltd., Korea", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Korea, Ltd., Korea", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}